Plasma Adrenomedullin Levels in Type 1 Diabetes: Relationship with clinical parameters
- M T García-Unzueta, MD,
- C Montalbán, MD,
- C Pesquera, MD,
- J R Berrazueta, MD and
- J A Amado, MD
- Endocrine Unit, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria Santander, Spain
- Cardiology Service, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria Santander, Spain
- Address correspondence and reprint requests to J.A. Amado, S. Endocrinologia, Hospital Universitario Marqués de Valdecilla, Valdecilla St., 39008 Santander, Spain. E-mail: amadoja{at}galeno.medi.unican.es
Abstract
OBJECTIVE To assess the relationship between plasma adrenomedullin (AM) levels and the presence of microvascular complications in type 1 diabetic patients.
RESEARCH DESIGN AND METHODS We measured plasma AM and cAMP levels in 103 type 1 diabetic patients (46 without complications, 24 with retinopathy only, 14 with microalbuminuria but normal kidney function, and 19 with renal insufficiency) and 41 matched healthy control subjects.
RESULTS Patients with renal insufficiency had higher levels of AM and cAMP than all other groups. Patients with only retinopathy showed a trend to have higher levels than patients without complications. There were no differences among all other groups. There was a significant correlation between AM and cAMP in the total diabetic group (rs = 0.36, P < 0.001) but not in the control group. In multiple regression analysis, plasma AM demonstrated significant relationships with creatinine clearance (β = −0.31, P = 0.004) and duration of the disease (β = 0.28, P = 0.008).
CONCLUSIONS Plasma AM and cAMP are increased in type 1 diabetic patients with renal insufficiency. Creatinine clearance (CrClc) and duration of the disease are related to plasma AM levels in these patients.
- Received August 26, 1997.
- Accepted February 19, 1998.
- Copyright © 1998 by the American Diabetes Association
